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Abstract: Starting from readily available allylglycine, a tandem hydroformylation-hemiaminal formation reaction has been 
developed for the synthesis of chiral functionalized piperidines, with very good diastereoselectivity and branched regioselectivity 
using Rh/(S,S,S)-BOBPHOS catalysts. Tandem hydroformylation-hemiacetal formation also proceeds with good 
diastereoselectivity (88:12), with the hemiacetal product being hydrogenated with retention of stereochemistry, to give a chiral 
intermediate used in the synthesis of the new antibiotic, Nemonoxacin. 
Hydroformylation of terminal alkenes generally favours the 
linear aldehyde; sometimes with excellent selectivity.1 Linear-
selective hydroformylation is quite a robust reaction at large 
scale, but also as synthetic methodology for the synthesis of 
complex molecules.2 Most examples of branched-selective 
hydroformylation make use of alkenes that have an electronic 
bias that encourages branched aldehyde formation. Thus some 
alkenes such as vinyl arene derivatives,3 acrylic acid 
derivatives 4 and vinyl benzoates/acetates5 almost exclusively 
form branched products. Alkenes of type RCH2CH=CH2 with 
a smaller electronic bias in the allylic position can also lead to 
some branched selectivity (60 to 90%).6 Rh/BOBPHOS 
(Figure 1) catalysts appear to be unique, at present,7,8 in that 
they are also able to give useful levels of branched 
regioselectivity7 and enantioselectivity in hydroformylation of 
unbiased alkenes.  
This type of branched selective hydroformylation is now 
being intensively investigated for the production of various 
industrial chemicals.9 However, a significant extension would 
be if the unusual branched selectivity could be used 
advantageously in the synthesis of chiral building blocks for 
organic synthesis. Of special interest was to evaluate if 
functionalized but unbiased alkenes could be hydroformylated 
with branched regioselectivity, such that functionalized chiral 
heterocycles could be made. A further extension would be to 
investigate one-pot hydroformylation-cyclization reactions 
that could lead to these targets in an especially efficient way.  
Here we report a study on the hydroformylation of various 
allylglycine derivatives, which enables an efficient synthesis 
of tert-butyl ((2S,4S)-1,5-dihydroxy-4-methylpentan-2-
yl)carbamate 7, used in the synthesis of the recently launched 
antibiotic Nemonoxacin 9 (Scheme 1).10 We also demonstrate 
a tandem diastereoselective hydroformylation-hemiaminal 
formation reaction with branched regioselectivity to give 
functionalized piperidines. 
Scheme 1. Synthesis of Nemonoxacin 
 
We first investigated the hydroformylation of readily 
available allylglycine derivatives, benzyl-2-(1,3-
dioxoisoindolin-2-yl)pent-4-enoate, 10a, and benzyl-2-
(dibenzylamino)pent-4-enoate, 11a (N-Boc protected 
allylglycine esters could not be used). As shown in Table 1, 
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the use of various standard hydroformylation catalysts using  
ligands such as PPh3, 1,3,5,7-tetramethyl-6-phenyl-2,4,8- 
trioxa-6-phosphaadamantane (MeCgPPh),11 XANTPHOS1f,12 or 
Ph-BPE13 do not give high yields of the desired isomer. 
Figure 1. Ligands used in achiral and asymmetric 
hydroformylation 
Table 1. Hydroformylation of benzyl -2-(1,3-
dioxoisoindolin-2-yl)pent-4-enoate, 10a, and 2-
(dibenzylamino)pent-4-enoate, 11a 
 
 
(a) Standard reaction conditions, substrate (0.45 mmol), 
[Rh(acac)(CO)2] = 0.4 mol%, L = 2 mol%, toluene, syngas used = 
5 bar with BOBPHOS, 10 bar with all other ligands, time = 16 h 
(b) The reaction shows high chemoselectivity with mass balance 
being unreacted alkene, determined by 1H NMR, using I.S (1-
methylnapthalene). (c) d.r = (S,R)-10b/(S,S)-10b’ (for entries 3-6 
& 8), (R,R)-10b’/(R,S)-10b (for entry 7), (S,R)-11b/(S,S)-11b’ (for 
entries 9 and 11) or (R,R)-11b’/(R,S)-11b (for entry 12) (S,S)-
11b’/(S,R)-11b (for entries 10 & 13) (d) See ref 12 (e) Isolated 
yield = 68% (f) Isolated yield = 62% 
The results obtained using commercially available7b Rh / 
BOBPHOS are quite a contrast providing the correct 
enantiomer of BOBPHOS is matched with the correct 
enantiomer of the allylglycine derivative; there is a dramatic 
increase in branched selectivity (1.9:1 to 6.8:1), yield and 
diastereoselectivity (74:26 to 98:2) when using (S)-10a, as 
opposed to (R)-10a, if using Rh/(R,R,R)-1 as the catalyst 
(entries 7 and 8, Table 1). The highest selectivity in the 
hydroformylation of (S)-10a led to (S,R)-10b as the major 
product. The same matching effect occurs in the dibenzyl 
protected amine, 11a. The (S,S,S)-1 catalyst is matched to the 
(S)-allylglycine derivative: this leads to the best selectivity and 
the diastereomer (S,S)-11b’, which is needed for the synthesis 
of the drug intermediate 7. 
 
Reduction of aldehydes 11b/11b’ to obtain the hydroxy-
ester 12 was possible by hydrogenation catalysed by Ru-
MACHO-BH,14 with retention of stereochemistry (the 
compounds in Scheme 2 were all used as diastereomeric 
mixtures from the hydroformylation reactions of Table 1, entry 
13). Hydrogenation of α-chiral aldehydes is generally quite 
challenging since typical catalysts for carbonyl reduction use 
basic conditions that cause racemization.4a,14a In studies on 
ester hydrogenation of either 10b/10b’ or 11b/11b’, reduction 
of both aldehyde and ester group with retention was not 
possible (see supporting information (SI)). Reduction to the 
(S,S)-benzyl-diol 13, was carried out easily with LiAlH4, with 
full retention of stereochemistry. Debenzylation of the diol 
was successful using Pearlman’s catalyst before reprotecting 
with di-tert-butyl dicarbonate. This gave tert-butyl ((2S,4S)-
1,5-dihydroxy-4-methylpentan-2-yl)carbamate, 7 (Scheme 2), 
which is an intermediate enroute to Nemonoxacin 9. 
Scheme 2. Synthesis of tert-butyl ((2S,4S)-1,5-dihydroxy-4-
methylpentan-2-yl)carbamate, 7 
 
Tandem enantioselective hydroformylation-hemiacetal 
formation has rarely been observed,6i,15 so we considered this 
as an alternative strategy. Tribenzylated allylglycine 11a, 
could be successfully reduced to (S)-2-(dibenzylamino)pent-4-
en-1-ol, 14, using DIBAL-H in 91% yield (Scheme 3).16 The 
hydroformylation of alcohol 14 can be performed selectively 
using either (R,R,R)-1 or (S,S,S)-1. (R,R,R)-1 obtains the best 
results in the hydroformylation of 14, leading to 83% of the 
hemiacetal, 15, with no branched aldehyde observed, and only 
17% linear aldehyde (effective b:l 4.9:1); compared to 79% 
hemiacetal (effective b:l 3.8:1) when using (S,S,S)-1 (ie -the 
opposite diastereomeric combination is matched compared to 
the studies on 11a). The ratio of diastereomers in the 
hemiacetal mixture could not be determined by NMR. 
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(°C) 
conv (b) b:l dr(c) 
1 (S)-10a dppf 40 0 - - 
2 (S)-10a 4(d) 40 8 0:1 - 
3 (S)-10a PPh3 40 >99 1:1 61:39 
4 (S)-10a 3 40 >99 0.8:1 61:39 
5 (S)-10a (R,R)-2 40 35 2.3:1 84:16 
6 (S)-10a (R,R,R)-1 40 >99 5.3:1 96:4 
7 (R)-10a (R,R,R)-1 25 48 1.9:1 74:26 
8(e) (S)-10a (R,R,R)-1 25 92 6.8:1 98:2 
9 (S)-11a 3 40 97 0.6:1 63:37 
10 (rac)-11a (R,R,R)-1 40 89 2.6:1 55:45 
11 (S)-11a (R,R,R)-1 40 92 2:1 92:8 
12 (R)-11a (R,R,R)-1 40 97 4:1 96:4 
13(f) (S)-11a (S,S,S)-1 40 >99 4:1 94:6 
However oxidation of the crude hemiacetal mix delivered 
lactone 17, and the ratio of diastereomers was found to be 93:7 
when formed using (R,R,R)-1 (88:12  when formed using 
(S,S,S)-1) by 1H NMR.  
To investigate if the hydroxyl moiety had an impact on the 
selectivity of the reaction, we hydroformylated the PMB 
(PMB = p-Methoxybenzyl) protected analogue, 18. When (S)-
N,N-dibenzyl-1-((4-methoxybenzyl)oxy)pent-4-en-2-amine 18 
was subjected to our hydroformylation conditions, we found 
the selectivity was slightly less than that of its non-protected 
counterpart, obtaining b:l of 3.3:1 and 91% diastereoselectivity 
(Scheme 4). We note the branched selectivity is relatively 
similar to that obtained on a PMB protected homo-allyl 
alcohol that lacks the amino function, 1-((but-3-en-1-
yloxy)methyl)-4-methoxybenzene, which gives 3.8:1 b:l 
selectivity and er of 94:6 (see SI). The higher regioselectivity 
and different matched combination of substrate and catalyst 
shows that the alcohol exerts some influence on the 
hydroformylation, perhaps by coordination to Rh. 
Scheme 3. Tandem hydroformylation-hemiacetal 
formation and subsequent oxidation and hydrogenation. 
 
Scheme 4. Hydroformylation of (S)-18. 
 
 
 We were also pleased to find that the hemiacetal 15 could 
be hydrogenated using Ru-MACHO-BH14 with retention of 
stereochemistry, since catalytic hydrogenation of an α-chiral 
hemiacetal does not seem to have been reported before. 
(2S,4S)-2-(dibenzylamino)-4-methylpentane-1,5-diol, 13, 
utilized in the synthesis of Nemonoxacin, was isolated in 70% 
yield (with the ratio of diastereomers retained from the 
hydroformylation-hemi-acetal formation, Scheme 3). 
Following the success of tandem hydroformylation-hemiacetal 
formation, we then considered a tandem hydroformylation-
hemiaminal formation. While this work was in progress, the 
first report on tandem asymmetric hydroformylation-
hemiaminal formation appeared, described as an ‘interrupted 
hydroaminomethylation’. This important contribution makes 
use of substrates that are strongly biased towards branched 
aldehyde formation α- to an aromatic ring, and also requires a 
N-tosylate protecting group.17 A tandem hydroformylation-
hemiaminal formation that uses an unbiased alkene and 
delivers a very efficient synthesis of functionalized piperidines 
now seemed feasible due to the selectivity of [Rh]/BOBPHOS 
catalysts. Adapting a procedure by Huang et al18 easily 
converted the (S)-benzyl ester derivative, 11a, to (S)-N-benzyl-
2-(dibenzylamino)pent-4-enamide 21 in a good yield (82%). 
The hydroformylation of this amide not only led to very good 
selectivity to the hemiaminal, 21h, (<1% branched aldehyde, 
22% linear aldehyde, 21l) but also leads exclusively to 
essentially one diastereomer by 1H NMR, when using (S,S,S)-
BOBPHOS (Scheme 5). The reduction of the hemiaminal to 
the desired piperidine equivalent can be achieved in two 
different ways; the hemiaminal, 21h, can be directly reduced 
using LiAlH4, reducing both the amide and hemiaminal 
functionality, or the hemiaminal can be oxidized19  to the 
dicarbonyl- derivative, 22, which can be reduced using LiAlH4 
to the functionalized piperidine, 23, (Scheme 5). Application 
of either oxidation or reduction to these substrates adds 
versatility to the chiral building blocks that can be synthesised 
using this methodology.  
Using allylglycine as a starting material, which can be 
produced very efficiently using enzymatic methods,20 the 
synthesis of tert-butyl ((2S,4S)-1,5-dihydroxy-4-methylpentan-
2-yl)carbamate 7 has been achieved, which is a key 
intermediate in the synthesis of Nemonoxacin.10 Tandem 
hydroformylation-cyclization reactions have also been 
developed for the synthesis of both functionalised piperidines 
and other 6-membered heterocycles. Despite the substrates 
used not being prone toward branched aldehyde formation, 
useful selectivity has been observed using the Rh/ BOBPHOS 
catalyst. 
Scheme 5. Tandem hydroformylation-hemiaminal 
formation and subsequent oxidation and hydrogenation 
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